Sayit Mahmut Erdogan
Assistant Professor
1 - 1 out of 1Page size: 10
- 2023
- Published
First-in-human use of a modular capsid virus-like vaccine platform: An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
Smit, M. J., Sander, A. F., Ariaans, M. B. P. A., Fougeroux, C., Heinzel, C., Fendel, R., Esen, M., Kremsner, P. G., Ter Heine, R., Wertheim, H. F., Idorn, M., Paludan, S. R., Underwood, A. P., Binderup, A., Ramirez, S., Bukh, J., Soegaard, M., Erdogan, S. M., Gustavsson, T., Clemmensen, S. & 14 others, , 2023, In: The Lancet Microbe. 4, 3, p. e140-e148Research output: Contribution to journal › Journal article › Research › peer-review
ID: 231845922
Most downloads
-
218
downloads
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
55
downloads
Development of a bispecific immune engager using a recombinant malaria protein
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
52
downloads
First-in-human use of a modular capsid virus-like vaccine platform: An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
Research output: Contribution to journal › Journal article › Research › peer-review
Published